VIMTALABS638.50

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹1,416 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
31/12/2024
Returns
Return on Common Equity17.6617.1012.8312.83
Return on Assets13.4513.3010.2510.25
Return on Capital Employed21.9521.0515.2015.20
Return on Invested Capital17.4317.8712.1617.93
Margins
EBITDA Margin28.8529.8327.2733.30
Operating Margin20.4720.1816.5316.53
Incremental Operating Margin18.14-16,340.85
Pretax Margin20.0120.4317.1223.39
Net Income Margin14.8515.1412.8918.26
FCF Margin7.3111.98-4.93-4.93
Additional
Effective Tax Rate25.7825.8924.7324.74
Dvd Payout Ratio10.709.1810.80
Sustainable Growth Rate15.7715.5311.4412.83
Incremental Operating Margin %18.14-16,340.85139.68
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.